🇯🇵·4d agoIndustry
FDA Accepts Shionogi’s sNDA for Fetroja® (cefiderocol) for Use in Pediatric Patients with Serious Infections Caused by Susceptible Gram-negative Bacteria Submission intends to address a critical therapeutic gap for vulnerable young patients facing drug-resistant pathogens
Publisher
S
Shionogi & Co. News
Japan
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Shionogi & Co. News
- Region
- Japan
- Scope
- Industry
- Published
- July 17, 2026
- Language
- EN
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on shionogi.com
Leave the platform to read the original full article on the publisher site.
Source: Shionogi & Co. News
Scope: Industry
Related coverage
More related coverage
Techcyte/37m ago
Techcyte Marks 11 Million AI-Assisted Scans Across Its Global Platform
Nippon Shinyaku News/1h ago
譲渡制限付株式報酬としての自己株式の処分に関するお知らせ
Merck & Co. (MSD) News/2h ago
Investigational Once-weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy
Takeda News/3h ago